While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent trial. The study enhances Lilly's position in the obesity drug market, ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Emmy-winning actor Annie Murphy stops by TODAY to talk about the long-awaited Season 2 of “Nine Perfect Strangers” based on ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...